S

SWK Holdings Corp
NASDAQ:SWKH

Watchlist Manager
SWK Holdings Corp
NASDAQ:SWKH
Watchlist
Price: 15.9 USD Market Closed
Market Cap: $192.4m

P/B

0.8
Current
34%
More Expensive
vs 3-y average of 0.6

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.8
=
Market Cap
$192.3m
/
Total Equity
$235.1m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
0.8
=
Market Cap
$192.3m
/
Total Equity
$235.1m

Valuation Scenarios

SWK Holdings Corp is trading above its 3-year average

If P/B returns to its 3-Year Average (0.6), the stock would be worth $11.82 (26% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-26%
Maximum Upside
+207%
Average Upside
63%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 0.8 $15.9
0%
3-Year Average 0.6 $11.82
-26%
5-Year Average 0.6 $12.52
-21%
Industry Average 1.6 $30.51
+92%
Country Average 2.5 $48.86
+207%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 10 946 companies
9th percentile
0.8
Low
0 — 1.5
Typical Range
1.5 — 4.8
High
4.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.5
Median 2.5
70th Percentile 4.8
Max 147 580.5

SWK Holdings Corp
Glance View

Market Cap
192.4m USD
Industry
Financial Services

SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.

SWKH Intrinsic Value
16.63 USD
Undervaluation 4%
Intrinsic Value
Price $15.9
S
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett